We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.64 per share in its forthcoming report, representing a decline of 1.5% year over year. Revenues are projected to reach $21.38 billion, declining 13.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Johnson & Johnson metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Sales- MedTech- Total' will reach $7.93 billion. The estimate indicates a change of +5.9% from the prior-year quarter.
The average prediction of analysts places 'Sales- Innovative Medicine- WW' at $13.44 billion. The estimate suggests a change of +0.2% year over year.
According to the collective judgment of analysts, 'Sales- MedTech- Orthopaedics- Trauma- WW' should come in at $778.57 million. The estimate indicates a year-over-year change of +2.9%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' of $736.53 million. The estimate suggests a change of +1% year over year.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics- Hips- US' will likely reach $250.20 million. The estimate points to a change of +3.8% from the year-ago quarter.
Analysts expect 'Sales- MedTech- Orthopaedics- Hips- International' to come in at $148.34 million. The estimate indicates a change of -0.4% from the prior-year quarter.
The consensus among analysts is that 'Sales- MedTech- Orthopaedics- Knees- US' will reach $232.66 million. The estimate suggests a change of +3% year over year.
Analysts predict that the 'Sales- MedTech- Orthopaedics- Knees- International' will reach $146.04 million. The estimate indicates a change of +2.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- MedTech- Orthopaedics- Trauma- US' should arrive at $500.35 million. The estimate indicates a change of +1.9% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Orthopaedics- Trauma- International' stands at $278.12 million. The estimate indicates a year-over-year change of +4.2%.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' reaching $408.28 million. The estimate indicates a change of +0.6% from the prior-year quarter.
Analysts forecast 'Organic Sales Growth (Operational growth)' to reach 3.9%. Compared to the present estimate, the company reported 9% in the same quarter last year.
Over the past month, shares of Johnson & Johnson have returned -6.8% versus the Zacks S&P 500 composite's +0.8% change. Currently, JNJ carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.64 per share in its forthcoming report, representing a decline of 1.5% year over year. Revenues are projected to reach $21.38 billion, declining 13.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Johnson & Johnson metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Sales- MedTech- Total' will reach $7.93 billion. The estimate indicates a change of +5.9% from the prior-year quarter.
The average prediction of analysts places 'Sales- Innovative Medicine- WW' at $13.44 billion. The estimate suggests a change of +0.2% year over year.
According to the collective judgment of analysts, 'Sales- MedTech- Orthopaedics- Trauma- WW' should come in at $778.57 million. The estimate indicates a year-over-year change of +2.9%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' of $736.53 million. The estimate suggests a change of +1% year over year.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics- Hips- US' will likely reach $250.20 million. The estimate points to a change of +3.8% from the year-ago quarter.
Analysts expect 'Sales- MedTech- Orthopaedics- Hips- International' to come in at $148.34 million. The estimate indicates a change of -0.4% from the prior-year quarter.
The consensus among analysts is that 'Sales- MedTech- Orthopaedics- Knees- US' will reach $232.66 million. The estimate suggests a change of +3% year over year.
Analysts predict that the 'Sales- MedTech- Orthopaedics- Knees- International' will reach $146.04 million. The estimate indicates a change of +2.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- MedTech- Orthopaedics- Trauma- US' should arrive at $500.35 million. The estimate indicates a change of +1.9% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Orthopaedics- Trauma- International' stands at $278.12 million. The estimate indicates a year-over-year change of +4.2%.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' reaching $408.28 million. The estimate indicates a change of +0.6% from the prior-year quarter.
Analysts forecast 'Organic Sales Growth (Operational growth)' to reach 3.9%. Compared to the present estimate, the company reported 9% in the same quarter last year.
View all Key Company Metrics for Johnson & Johnson here>>>
Over the past month, shares of Johnson & Johnson have returned -6.8% versus the Zacks S&P 500 composite's +0.8% change. Currently, JNJ carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>